1-8 of 8
Jurriaan Brouwer-Visser
Close
Sort by
Journal Articles

Trial in Progress: Phase 1 Trial Evaluating the Safety and Tolerability of Odronextamab in Combination with Cemiplimab in Relapsed/Refractory Aggressive B-Cell Non-Hodgkin Lymphoma

Cecilia Carpio, Manjusha Namuduri, Nazia Iqbal, Dishan Liu, Nickolas Sophos, Min Zhu, Ayesha Sabir, Jurriaan Brouwer-Visser, Aafia Chaudhry, Hesham Mohamed, Alejandro Martín García-Sancho
Journal: Blood
Blood (2023) 142 (Supplement 1): 3100.
https://doi.org/10.1182/blood-2023-179964
Published: 2023
Journal Articles

Odronextamab Monotherapy for the Treatment of Relapsed/Refractory (R/R) Follicular Lymphoma (FL) and Diffuse Large B-Cell Lymphoma (DLBCL): Focus on Clinical Pharmacology and Pharmacometrics in the ELM-1 and ELM-2 Studies

Min Zhu, Daniela Conrado, Kamal Srinivasan, Jurriaan Brouwer-Visser, Hong Yan, Hesham Mohamed, Aafia Chaudhry, Srikanth Ambati, Lutz Harnisch, John D Davis
Journal: Blood
Blood (2023) 142 (Supplement 1): 1436.
https://doi.org/10.1182/blood-2023-180675
Published: 2023
Journal Articles

Circulating Tumor DNA Analysis Associates with Progression-Free Survival (PFS) with Odronextamab Monotherapy in Relapsed/Refractory (R/R) Follicular Lymphoma (FL) and Diffuse Large B-Cell Lymphoma (DLBCL): Identification of Minimal Residual Disease Status and High-Risk Subgroups from the Phase 2 ELM-2 Study

Jon E. Arnason, Jurriaan Brouwer-Visser, Stefano Luminari, David Tucker, Tae Min Kim, Won Seog Kim, Laura Magnano, Dylan Sun, Jessica Cai, Kamil Cygan, Srikanth Ambati, Hesham Mohamed, Aafia Chaudhry, Vladimir Jankovic
Journal: Blood
Blood (2023) 142 (Supplement 1): 427.
https://doi.org/10.1182/blood-2023-179812
Published: 2023
Journal Articles

Odronextamab Demonstrates Durable Complete Responses in Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Progressing after CAR-T Therapy: Outcomes from the ELM-1 Study

Jennifer L. Crombie, Matthew Matasar, Max S. Topp, John N. Allan, Jeffrey A. Barnes, Jon E. Arnason, Jean-Marie Michot, Neta Goldschmidt, Susan M. O'Brien, Uri Abadi, Irit Avivi Mazza, Jessica Cai, Dina M. Flink, Min Zhu, Jurriaan Brouwer-Visser, Hesham Mohamed, Aafia Chaudhry, Srikanth Ambati, Steve M Ansell
Journal: Blood
Blood (2023) 142 (Supplement 1): 4461.
https://doi.org/10.1182/blood-2023-181602
Published: 2023
Journal Articles

A Quantitative Systems Pharmacology Modeling Framework for Evaluation of Cytokine Release Mediated By Intravenous Odronextamab Monotherapy in Patients with B-Cell Non-Hodgkin Lymphoma

Masood Khaksar Toroghi, Min Zhu, Jurriaan Brouwer-Visser, Srikanth R. Ambati, Hesham Mohamed, Aafia Chaudhry, John D. Davis, A. Thomas DiCioccio
Journal: Blood
Blood (2022) 140 (Supplement 1): 11930–11931.
https://doi.org/10.1182/blood-2022-158412
Published: 2022
Journal Articles

Optimization of Intravenous Odronextamab Step-up Regimen for Reducing the Risk of High-Grade Cytokine Release Syndrome

Min Zhu, Jurriaan Brouwer-Visser, Srikanth R. Ambati, Hesham Mohamed, Vladimir Jankovic, Fang Wang, Hong Yan, Jingxian Cai, Carolina Leite De Oliveira, Melanie Ufkin, John D. Davis, Aafia Chaudhry, Masood Khaksar Toroghi
Journal: Blood
Blood (2022) 140 (Supplement 1): 11560–11561.
https://doi.org/10.1182/blood-2022-158415
Published: 2022
Journal Articles

Baseline Biomarkers of T-Cell Function Correlate with Clinical Responses to Odronextamab (REGN1979), and Loss of CD20 Target Antigen Expression Identified As a Mechanism of Treatment Resistance

Jurriaan Brouwer-Visser, PhD, Nathalie Fiaschi, PhD, Raquel P. Deering, PhD, Ankur Dhanik, PhD, Kamil J. Cygan, PhD, Wen Zhang, PhD, Se Jeong, MPH, Stephane Pourpe, MS, Lauren Boucher, Sara Hamon, PhD, Max S. Topp, MD, Rajat Bannerji, MDPhD, Johannes Duell, MD, Ranjana Advani, MD, Dina M. Flink, PhD, Aafia Chaudhry, MD MBA, MS, Andres Sirulnik, MD PhD, Andrew J. Murphy, PhD, David M. Weinreich, MD, George D. Yancopoulos, MD PhD, Gavin Thurston, PhD, Srikanth R. Ambati, MBBS, MD, Vladimir Jankovic, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 10–11.
https://doi.org/10.1182/blood-2020-137499
Published: 2020
Journal Articles

A Phase 2 Study of Odronextamab (REGN1979), a CD20 x CD3 Bispecific Antibody, in Patients with Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma

Tae Min Kim, MD PhD, Arancha Alonso, MD, Miles Prince, MD, Michal Taszner, MD, Seok-Goo Cho, MD, PhD, Don A. Stevens, MD, Michelle Poon, MD, Francesca Lim, MBBS, BSc, MRCP (UK), Steven Le Gouill, MD PhD, Cecilia Carpio, MD, Mary-Margaret Keating, MD FRCPC, Lieve Adriaens, PharmD, Melanie Ufkin, PhD, Ayesha Sabir, BSc, Jingjin Li, PhD, Vladimir Jankovic, MD, Min Zhu, PhD, Jurriaan Brouwer-Visser, PhD, Siyang Leng, MD MS, L. Andres Sirulnik, MD PhD, Aafia Chaudhry, MD MBA, MS, Srikanth R. Ambati, MBBS, MD, Kim Won Seog, MD PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 28–29.
https://doi.org/10.1182/blood-2020-136344
Published: 2020